New Drug Targets for the Treatment of Obesity

There is a huge void in the current pharmacological treatment options for obesity. This gap is surprising given the high prevalence and associated costs of obesity. Many factors have prevented active drug development, including the poor safety and efficacy of earlier antiobesity drugs. However, ther...

Full description

Saved in:
Bibliographic Details
Published in:Clinical pharmacology and therapeutics 2011-07, Vol.90 (1), p.40-51
Main Authors: Powell, AG, Apovian, CM, Aronne, LJ
Format: Article
Language:English
Subjects:
Animals
Anti-Obesity Agents - adverse effects
Anti-Obesity Agents - pharmacology
Anti-Obesity Agents - therapeutic use
Biological and medical sciences
Clinical Trials, Phase I as Topic
Clinical Trials, Phase II as Topic
Clinical Trials, Phase III as Topic
Drug Combinations
Drug Design
Drug Therapy, Combination
Energy Metabolism - drug effects
Humans
Medical sciences
Metabolic diseases
Obesity
Obesity - drug therapy
Pharmacology. Drug treatments
Receptors, Drug - drug effects
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:There is a huge void in the current pharmacological treatment options for obesity. This gap is surprising given the high prevalence and associated costs of obesity. Many factors have prevented active drug development, including the poor safety and efficacy of earlier antiobesity drugs. However, there are now several compelling targets on the horizon. The new generation of antiobesity drugs offers hope for the management of obesity, but no single agent is likely to be a panacea. Rather, obesity will need to be managed like many other chronic diseases, with combination therapies and long‐term treatment in order to achieve sustained success. New targets have arisen as more research has been performed to understand the complex circuitry that controls energy homeostasis. The goal of this review is to discuss the latest pharmacological agents and strategies that are under development and that may eventually be used for the treatment of obesity. Clinical Pharmacology & Therapeutics (2011) 90 1, 40–51. doi:10.1038/clpt.2011.82
ISSN:0009-9236
1532-6535
DOI:10.1038/clpt.2011.82